 Tissue will be collected at baseline and at progression clinical or radiological. Patients may remain on treatment after progression at the discretion of the investigator as long as they are still experiencing clinical benefit. We anticipate that up to 50 of patients may continue on therapy post-progression for 2-8 weeks. 